Hypoxemia in patients with COPD: Cause, effects, and disease progression

International Journal of COPD

Volumn 6, Issue 1, 2011, Pages 199-208

  Kent, Brian D ^a,b   Mitchell, Patrick D ^a   Mcnicholas, Walter T ^a,b  

^a ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

^b UNIVERSITY COLLEGE DUBLIN   (Ireland)

Author keywords

COPD; Hypoxia; Infammation; Pulmonary hypertension; Sleep

Indexed keywords

ANGIOTENSIN ANTAGONIST; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; ENDOTHELIN RECEPTOR ANTAGONIST; INFLIXIMAB; LONG ACTING DRUG; LOSARTAN; OXYHEMOGLOBIN; PHOSPHODIESTERASE V INHIBITOR; PROSTACYCLIN DERIVATIVE; THEOPHYLLINE;

CARDIOVASCULAR RISK; CAUSAL ATTRIBUTION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL EFFECTIVENESS; COGNITIVE DEFECT; DISEASE EXACERBATION; DISEASE PREDISPOSITION; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; ERYTHROCYTOSIS; EXERCISE TOLERANCE; HUMAN; HYPOXEMIA; HYPOXIA; INFLAMMATORY DISEASE; LUNG HEMODYNAMICS; MYOPATHY; NONHUMAN; OXYGEN THERAPY; PHLEBOTOMY; POLYCYTHEMIA; POSITIVE END EXPIRATORY PRESSURE; PULMONARY HYPERTENSION; QUALITY OF LIFE; RESPIRATORY FAILURE; REVIEW; RISK ASSESSMENT; SLEEP APNEA SYNDROME; SLEEP DISORDERED BREATHING; SLEEP QUALITY; SURVIVAL RATE; SYSTEMIC DISEASE; TREATMENT DURATION; ANOXIA; DISEASE COURSE; EXERCISE; HOSPITALIZATION; INFLAMMATION; LUNG ALVEOLUS; LUNG GAS EXCHANGE; PATHOPHYSIOLOGY; SKELETAL MUSCLE; SLEEP; TREATMENT OUTCOME;

ANOXIA; DISEASE PROGRESSION; EXERCISE; HUMANS; HYPERTENSION, PULMONARY; INFLAMMATION; MUSCLE, SKELETAL; OXYGEN INHALATION THERAPY; POLYCYTHEMIA; PULMONARY ALVEOLI; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; PULMONARY GAS EXCHANGE; SEVERITY OF ILLNESS INDEX; SLEEP; TREATMENT OUTCOME;

EID: 80051819239     PISSN: 11769106     EISSN: 11782005     Source Type: Journal    
DOI: 10.2147/COPD.S10611     Document Type: Review

References (110)

1. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet. 1997;349:1498-1504.
2. Rabe KF, Hurd S, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2007;176:532-555.
3. Tashkin D P, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008;359:1543-1554.
4. Martinez FJ, Foster G, Curtis JL, et al. Predictors of mortality in patients with emphysema and severe airflow obstruction. Am J Respir Crit Care Med. 2006;173:1326-1334.
5. Kim V, Benditt JO, Wise RA, Sharafkhaneh A. Oxygen therapy in chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2008;5:513-518.
6. Gibson GJ. Clinical Tests of Respiratory Function. 3rd ed. London: Hodder Arnold; 2009.
7. Wagner PD, Dantzker DR, Dueck R, Clausen JL, West JB. Ventilation-perfusion inequality in chronic obstructive pulmonary disease. J Clin Invest. 1977;59:203-216.
8. Barbera JA, Ramirez J, Roca J, Wagner PD, Sanchez-Lloret J, Rodriguez-Roisin R. Lung structure and gas exchange in mild chronic obstructive pulmonary disease. Am Rev Respir Dis. 1990;141:895-901.
9. Sandek K, Bratel T, Hellstrom G, Lagerstrand L. Ventilation-perfusion inequality and carbon dioxide sensitivity in hypoxaemic chronic obstructive pulmonary disease (COPD) and effects of 6 months of long-term oxygen treatment (LTOT). Clin Physiol. 2001;21:584-593.
10. Barbera JA, Roca J, Ferrer A, et al. Mechanisms of worsening gas exchange during acute exacerbations of chronic obstructive pulmonary disease. Eur Respir J. 1997;10:1285-1291.
11. Franssen FM, O'Donnell DE, Goossens GH, Blaak EE, Schols AM. Obesity and the lung: 5. Obesity and COPD. Thorax. 2008;63: 1110-1117.
12. Young T, Palta M, Dempsey J, Skatrud J, Weber S, Badr S. The occurrence of sleep-disordered breathing among middle-aged adults. N Engl J Med. 1993;328:1230-1235.
13. Kessler R, Chaouat A, Schinkewitch P, et al. The obesity-hypoventilation syndrome revisited: A prospective study of 34 consecutive cases. Chest. 2001;120:369-376.
14. Flenley DC, Franklin DH, Millar JS. The hypoxic drive to breathing in chronic bronchitis and emphysema. Clin Sci. 1970;38: 503-518.
15. Bradley CA, Fleetham JA, Anthonisen NR. Ventilatory control in patients with hypoxemia due to obstructive lung disease. Am Rev Respir Dis. 1979;120:21-30.
16. Duranti R, Misuri G, Gorini M, Goti P, Gigliotti F, Scano G. Mechanical loading and control of breathing in patients with severe chronic obstructive pulmonary disease. Thorax. 1995;50:127-133.
17. Barbera JA, Roca J, Ramirez J, Wagner PD, Ussetti P, Rodriguez-Roisin R. Gas exchange during exercise in mild chronic obstructive pulmonary disease. Correlation with lung structure. Am Rev Respir Dis. 1991;144:520-525.
18. Dantzker DR, D'Alonzo GE. The effect of exercise on pulmonary gas exchange in patients with severe chronic obstructive pulmonary disease. Am Rev Respir Dis. 1986;134:1135-1139.
19. O'Donnell DE, D'Arsigny C, Fitzpatrick M, Webb KA. Exercise hypercapnia in advanced chronic obstructive pulmonary disease: The role of lung hyperinfation. Am J Respir Crit Care Med. 2002;166: 663-668.
20. Casanova C, Cote C, Marin JM, et al. Distance and oxygen desatura-tion during the 6-min walk test as predictors of long-term mortality in patients with COPD. Chest. 2008;134:746-752.
21. Stoller JK, Panos RJ, Krachman S, Doherty DE, Make B. Oxygen therapy for patients with COPD: Current evidence and the long-term oxygen treatment trial. Chest. 2010;138:179-187.
22. McNicholas WT. Impact of sleep in COPD. Chest. 2000;117: 48S-53S.
23. McNicholas WT. Chronic obstructive pulmonary disease and obstructive sleep apnea:Overlaps in pathophysiology, systemic inflammation, and cardiovascular disease. Am J Respir Crit Care Med. 2009;180:692-700.
24. Chaouat A, Weitzenblum E, Krieger J, Ifoundza T, Oswald M, Kessler R. Association of chronic obstructive pulmonary disease and sleep apnea syndrome. Am J Respir Crit Care Med. 1995;151:82-86.
25. Lee R, McNicholas WT. Obstructive sleep apnea in chronic obstructive pulmonary disease patients. Curr Opin Pulm Med. 2011;17:79-83.
26. Marin JM, Soriano JB, Carrizo SJ, Boldova A, Celli BR. Outcomes in patients with chronic obstructive pulmonary disease and obstructive sleep apnea: The overlap syndrome. Am J Respir Crit Care Med. 2010;182:325-331.
27. Cranston JM, Crockett AJ, Moss JR, Alpers JH. Domiciliary oxygen for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2005:CD001744.
28. Goldstein RS, Ramcharan V, Bowes G, McNicholas WT, Bradley D, Phillipson EA. Effect of supplemental nocturnal oxygen on gas exchange in patients with severe obstructive lung disease. N Engl J Med. 1984;310:425-429.
29. Mulloy E, McNicholas WT. Theophylline improves gas exchange during rest, exercise, and sleep in severe chronic obstructive pulmonary disease. Am Rev Respir Dis. 1993;148:1030-1036.
30. Mulloy E, McNicholas WT. Theophylline in obstructive sleep apnea. A double-blind evaluation. Chest. 1992;101:753-757.
31. Ryan S, Doherty LS, Rock C, Nolan GM, McNicholas WT. Effects of salmeterol on sleeping oxygen saturation in chronic obstructive pulmonary disease. Respiration. 2010;79:475-481.
32. McNicholas WT, Calverley PM, Lee A, Edwards JC. Long-acting inhaled anticholinergic therapy improves sleeping oxygen saturation in COPD. Eur Respir J. 2004;23:825-831.
33. Chaouat A, Naeije R, Weitzenblum E. Pulmonary hypertension in COPD. Eur Respir J. 2008;32:1371-1385.
34. Chaouat A, Bugnet AS, Kadaoui N, et al. Severe pulmonary hypertension and chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2005;172:189-194.
35. Scharf SM, Iqbal M, Keller C, Criner G, Lee S, Fessler HE. Hemodynamic characterization of patients with severe emphysema. Am J Respir Crit Care Med. 2002;166:314-322.
36. Thabut G, Dauriat G, Stern JB, et al. Pulmonary hemodynamics in advanced COPD candidates for lung volume reduction surgery or lung transplantation. Chest. 2005;127:1531-1536.
37. Abraham AS, Cole RB, Green ID, Hedworth-Whitty RB, Clarke S W, Bishop JM. Factors contributing to the reversible pulmonary hypertension of patients with acute respiratory failure studies by serial observations during recovery. Circ Res. 1969;24:51-60.
38. Weitzenblum E, Chaouat A. Cor pulmonale. Chron Respir Dis. 2009;6:177-185.
39. Redolf S, Yumino D, Ruttanaumpawan P, et al. Relationship between overnight rostral fuid shift and obstructive sleep apnea in nonobese men. Am J Respir Crit Care Med. 2009;179:241-246.
40. Elwing J, Panos RJ. Pulmonary hypertension associated with COPD. Int J Chron Obstruct Pulmon Dis. 2008;3:55-70.
41. Santos S, Peinado VI, Ramirez J, et al. Characterization of pulmonary vascular remodelling in smokers and patients with mild COPD. Eur Respir J. 2002;19:632-638.
42. Hambraeus-Jonzon K, Bindslev L, Mellgard AJ, Hedenstierna G. Hypoxic pulmonary vasoconstriction in human lungs. A stimulus-response study. Anesthesiology. 1997;86:308-315.
43. Dorrington KL, Clar C, Young JD, Jonas M, Tansley JG, Robbins PA. Time course of the human pulmonary vascular response to 8 hours of isocapnic hypoxia. Am J Physiol. 1997;273:H1126-H1134.
44. Weir EK, Lopez-Barneo J, Buckler KJ, Archer SL. Acute oxygen-sensing mechanisms. N Engl J Med. 2005;353:2042-2055.
45. Fuchs B, Sommer N, Dietrich A, et al. Redox signaling and reactive oxygen species in hypoxic pulmonary vasoconstriction. Respir Physiol Neurobiol. 2010;174:282-291.
46. Dinh-Xuan AT, Higenbottam TW, Clelland CA, et al. Impairment of endothelium-dependent pulmonary-artery relaxation in chronic obstructive lung disease. N Engl J Med. 1991;324:1539-1547.
47. McQuillan L P, Leung GK, Marsden PA, Kostyk SK, Kourembanas S. Hypoxia inhibits expression of eNOS via transcriptional and posttran-scriptional mechanisms. Am J Physiol. 1994;267:H1921-H1927.
48. Castaldi PJ, Hersh CP, Reilly JJ, Silverman EK. Genetic associations with hypoxemia and pulmonary arterial pressure in COPD. Chest. 2009;135:737-744.
49. Eddahibi S, Chaouat A, Morrell N, et al. Polymorphism of the serotonin transporter gene and pulmonary hypertension in chronic obstructive pulmonary disease. Circulation. 2003;108:1839-1844.
50. Eddahibi S, Chaouat A, Tu L, et al. Interleukin-6 gene polymorphism confers susceptibility to pulmonary hypertension in chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2006;3:475-476.
51. Yildiz P, Ofaz H, Cine N, Erginel-Unaltuna N, Erzengin F, Yilmaz V. Gene polymorphisms of endothelial nitric oxide synthase enzyme associated with pulmonary hypertension in patients with COPD. Respir Med. 2003;97:1282-1288.
52. Ulrich S, Hersberger M, Fischler M, et al. Genetic polymorphisms of the serotonin transporter, but not the 2a receptor or nitric oxide synthetase, are associated with pulmonary hypertension in chronic obstructive pulmonary disease. Respiration. 2010;79:288-295.
53. Kanazawa H, Okamoto T, Hirata K, Yoshikawa J. Deletion polymorphisms in the angiotensin converting enzyme gene are associated with pulmonary hypertension evoked by exercise challenge in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2000;162:1235-1238.
54. Nocturnal Oxygen Therapy Trial Group. Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: A clinical trial. Nocturnal Oxygen Therapy Trial Group. Ann Intern Med. 1980;93:391-398.
55. Medical Research Council Working Party. Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Report of the Medical Research Council Working Party. Lancet. 1981;1:681-686.
56. Blanco I, Gimeno E, Munoz PA, et al. Hemodynamic and gas exchange effects of sildenafl in patients with chronic obstructive pulmonary disease and pulmonary hypertension. Am J Respir Crit Care Med. 2010;181:270-278.
57. Weitzenblum E, Hirth C, Ducolone A, Mirhom R, Rasaholinjanahary J, Ehrhart M. Prognostic value of pulmonary artery pressure in chronic obstructive pulmonary disease. Thorax. 1981;36:752-758.
58. Bishop JM, Cross KW. Physiological variables and mortality in patients with various categories of chronic respiratory disease. Bull Eur Phys-iopathol Respir. 1984;20:495-500.
59. Oswald-Mammosser M, Weitzenblum E, Quoix E, et al. Prognostic factors in COPD patients receiving long-term oxygen therapy. Importance of pulmonary artery pressure. Chest. 1995;107: 1193-1198.
60. Epstein AA. A Contribution to the study of the chemistry of blood serum. J Exp Med. 1912;16:719-731.
61. Weber FP. The prognostic signifcance of secondary polycythaemia in cardio-pulmonary cases. Proc R Soc Med. 1913;6:83-98.
62. Nakamura A, Kasamatsu N, Hashizume I, et al. Effects of hemoglobin on pulmonary arterial pressure and pulmonary vascular resistance in patients with chronic emphysema. Respiration. 2000;67:502-506.
63. York EL, Jones RL, Menon D, Sproule BJ. Effects of secondary poly-cythemia on cerebral blood fow in chronic obstructive pulmonary disease. Am Rev Respir Dis. 1980;121:813-818.
64. Kohkhar N. Hyperuricemia and gout in secondary polycythemia due to chronic obstructive pulmonary disease. J Rheumatol. 1980;7: 114-116.
65. Ryan SF. Pulmonary embolism and thrombosis in chronic obstructive emphysema. Am J Pathol. 1963;43:767-773.
66. Cote C, Zilberberg MD, Mody SH, Dordelly LJ, Celli B. Haemoglobin level and its clinical impact in a cohort of patients with COPD. Eur Respir J. 2007;29:923-929.
67. Chambellan A, Chailleux E, Similowski T. Prognostic value of the hematocrit in patients with severe COPD receiving long-term oxygen therapy. Chest. 2005;128:1201-1208.
68. Similowski T, Agusti A, MacNee W, Schonhofer B. The potential impact of anaemia of chronic disease in COPD. Eur Respir J. 2006; 27:390-396.
69. Incalzi RA, Corsonello A, Pedone C, Battaglia S, Paglino G, Bellia V. Chronic renal failure: A neglected comorbidity of COPD. Chest. 2010;137:831-837.
70. Semenza GL. Regulation of oxygen homeostasis by hypoxia-inducible factor 1. Physiology (Bethesda). 2009;24:97-106.
71. Oren R, Beeri M, Hubert A, Kramer MR, Matzner Y. Effect of theophyl-line on erythrocytosis in chronic obstructive pulmonary disease. Arch Intern Med. 1997;157:1474-1478.
72. Vlahakos DV, Marathias KP, Kosmas EN. Losartan reduces hematocrit in patients with chronic obstructive pulmonary disease and secondary erythrocytosis. Ann Intern Med. 2001;134:426-427.
73. Weisse AB, Moschos CB, Frank MJ, Levinson GE, Cannilla JE, Regan TJ. Hemodynamic effects of staged hematocrit reduction in patients with stable cor pulmonale and severely elevated hematocrit levels. Am J Med. 1975;58:92-98.
74. Gan WQ, Man SF, Senthilselvan A, Sin DD. Association between chronic obstructive pulmonary disease and systemic infammation:A systematic review and a meta-analysis. Thorax. 2004;59: 574-580.
75. Agusti AG. Systemic effects of chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2005;2:367-370.
76. Sin DD, Man SF. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic infammation in chronic obstructive pulmonary disease. Circulation. 2003;107:1514-1519.
77. Dahl M, Vestbo J, Lange P, Bojesen SE, Tybjaerg-Hansen A, Nordestgaard BG. C-reactive protein as a predictor of prognosis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2007;175:250-255.
78. Garvey J F, Taylor CT, McNicholas WT. Cardiovascular disease in obstructive sleep apnoea syndrome: The role of intermittent hypoxia and infammation. Eur Respir J. 2009;33:1195-1205.
79. Ryan S, Taylor CT, McNicholas WT. Systemic infammation: A key factor in the pathogenesis of cardiovascular complications in obstructive sleep apnoea syndrome? Thorax. 2009;64:631-636.
80. Fitzpatrick S F, Tambuwala MM, Bruning U, et al. An intact canonical NF-{kappa}B pathway is required for infammatory gene expression in response to hypoxia. J Immunol. 2011;186:1091-1096.
81. Takabatake N, Nakamura H, Abe S, et al. The relationship between chronic hypoxemia and activation of the tumor necrosis factor-alpha system in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2000;161:1179-1184.
82. Sinden NJ, Stockley RA. Systemic infammation and comorbidity in COPD: A result of "overspill" of infammatory mediators from the lungs? Review of the evidence. Thorax. 2010;65:930-936.
83. Trayhurn P, Wang B, Wood IS. Hypoxia in adipose tissue: A basis for the dysregulation of tissue function in obesity? Br J Nutr. 2008;100: 227-235.
84. Pasarica M, Sereda OR, Redman LM, et al. Reduced adipose tissue oxygenation in human obesity: Evidence for rarefaction, macrophage chemotaxis, and inflammation without an angiogenic response. Diabetes. 2009;58:718-725.
85. Tkacova R, Ukropec J, Skyba P, et al. Increased adipose tissue expression of proinfammatory CD40, MKK4 and JNK in patients with very severe chronic obstructive pulmonary disease. Respiration. August 12, 2010. [Epub ahead of print].
86. Sin DD, Lacy P, York E, Man SF. Effects of futicasone on systemic markers of infammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2004;170:760-765.
87. Dentener MA, Creutzberg EC, Pennings HJ, Rijkers GT, Mercken E, Wouters EF. Effect of infiximab on local and systemic infammation in chronic obstructive pulmonary disease: A pilot study. Respiration. 2008;76:275-282.
88. Rennard SI, Fogarty C, Kelsen S, et al. The safety and effcacy of inf-liximab in moderate to severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2007;175:926-934.
89. Carpagnano GE, Kharitonov SA, Foschino-Barbaro M P, Resta O, Gramiccioni E, Barnes PJ. Supplementary oxygen in healthy subjects and those with COPD increases oxidative stress and airway infammation. Thorax. 2004;59:1016-1019.
90. Van Helvoort HA, Heijdra YF, Heunks LM, et al. Supplemental oxygen prevents exercise-induced oxidative stress in muscle-wasted patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2006;173:1122-1129.
91. Kim HC, Mofarrahi M, Hussain SN. Skeletal muscle dysfunction in patients with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2008;3:637-658.
92. Pouw EM, Ten Velde GP, Croonen BH, Kester AD, Schols AM, Wouters EF. Early non-elective readmission for chronic obstructive pulmonary disease is associated with weight loss. Clin Nutr. 2000;19:95-99.
93. Swallow EB, Reyes D, Hopkinson NS, et al. Quadriceps strength predicts mortality in patients with moderate to severe chronic obstructive pulmonary disease. Thorax. 2007;62:115-120.
94. Wust RC, Degens H. Factors contributing to muscle wasting and dysfunction in COPD patients. Int J Chron Obstruct Pulmon Dis. 2007;2:289-300.
95. Davidson AC, Leach R, George RJ, Geddes DM. Supplemental oxygen and exercise ability in chronic obstructive airways disease. Thorax. 1988;43:965-971.
96. Spruit MA, Gosselink R, Troosters T, et al. Muscle force during an acute exacerbation in hospitalised patients with COPD and its relationship with CXCL8 and IGF-I. Thorax. 2003;58:752-756.
97. Agusti A, Morla M, Sauleda J, Saus C, Busquets X. NF-kappaB activation and iNOS upregulation in skeletal muscle of patients with COPD and low body weight. Thorax. 2004;59:483-487.
98. Barreiro E, Schols AM, Polkey MI, et al. Cytokine profle in quadriceps muscles of patients with severe COPD. Thorax. 2008;63:100-107.
99. Couillard A, Maltais F, Saey D, et al. Exercise-induced quadriceps oxidative stress and peripheral muscle dysfunction in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2003;167:1664-1669.
100. Koechlin C, Maltais F, Saey D, et al. Hypoxaemia enhances peripheral muscle oxidative stress in chronic obstructive pulmonary disease. Thorax. 2005;60:834-841.
101. Bodine SC, Stitt TN, Gonzalez M, et al. Akt/mTOR pathway is a crucial regulator of skeletal muscle hypertrophy and can prevent muscle atrophy in vivo. Nat Cell Biol. 2001;3:1014-1019.
102. Favier FB, Costes F, Defour A, et al. Downregulation of Akt/mammalian target of rapamycin pathway in skeletal muscle is associated with increased REDD1 expression in response to chronic hypoxia. Am J Physiol Regul Integr Comp Physiol. 2010;298: R1659-R1666.
103. Jatta K, Eliason G, Portela-Gomes GM, et al. Overexpression of von Hippel-Lindau protein in skeletal muscles of patients with chronic obstructive pulmonary disease. J Clin Pathol. 2009;62:70-76.
104. Dodd JW, Getov SV, Jones PW. Cognitive function in COPD. Eur Respir J. 2010;35:913-922.
105. Incalzi RA, Gemma A, Marra C, Muzzolon R, Capparella O, Carbonin P. Chronic obstructive pulmonary disease. An original model of cognitive decline. Am Rev Respir Dis. 1993;148:418-424.
106. Thakur N, Blanc PD, Julian LJ, et al. COPD and cognitive impairment: The role of hypoxemia and oxygen therapy. Int J Chron Obstruct Pulmon Dis. 2010;5:263-269.
107. Krop HD, Block AJ, Cohen E. Neuropsychologic effects of continuous oxygen therapy in chronic obstructive pulmonary disease. Chest. 1973;64:317-322.
108. Croxton TL, Bailey WC. Long-term oxygen treatment in chronic obstructive pulmonary disease: Recommendations for future research: An NHLBI workshop report. Am J Respir Crit Care Med. 2006;174:373-378.
109. Moloney ED, Kiely JL, McNicholas WT. Controlled oxygen therapy and carbon dioxide retention during exacerbations of chronic obstructive pulmonary disease. Lancet. 2001;357:526-528.
110. Lacasse Y, LaForge J, Maltais F. Got a match? Home oxygen therapy in current smokers. Thorax. 2006;61:374-375.